Welcome to our dedicated page for Trenchant Technologies Capital news (Ticker: AITTF), a resource for investors and traders seeking the latest updates and insights on Trenchant Technologies Capital stock.
Trenchant Technologies Capital Corp. reports news centered on its role as a public investment issuer and blank-check or SPAC-type company. Recurring categories include private placements, common-share and warrant unit structures, working-capital financing, governance matters, and security-structure disclosures tied to AITTF and AITT.
Company news also covers technology-investment themes, including artificial intelligence, quantum computing, and genomics-driven digital-twin platforms connected with drug discovery and simulated clinical development. These updates describe Trenchant's focus on companies applying novel technologies to traditional business models.
Trenchant Technologies Capital (CSE: AITT, OTC: AITTF) will delay filing its audited annual financial statements for the year ended March 31, 2026, related MD&A, and CEO/CFO certificates beyond the July 29, 2026 deadline, due to unresolved matters related to a material investment and associated audit procedures.
The company has applied to the British Columbia Securities Commission for a temporary management cease trade order (MCTO) under NP 12-203, which, if granted, would restrict trading only by senior officers and insiders. Trenchant is not in insolvency proceedings and is committing additional internal resources to complete the audit and file the required documents.
Trenchant Technologies Capital Corp. (CSE: AITT, OTC: AITTF) closed the first tranche of its private placement of convertible debentures on July 10, 2026, issuing 500 debentures for gross proceeds of $500,000. The debentures bear 12% annual interest, mature 12 months from issuance, and are convertible at the holder’s option into common shares at $0.10 per share, subject to adjustments. Proceeds are intended for working capital and investments in portfolio or new opportunities. All securities carry a four‑month‑plus‑one‑day hold period.
An insider participated, triggering related‑party considerations under MI 61‑101, but Trenchant relies on exemptions as the fair market value involving the insider is below 25% of its market capitalization. Early warning disclosure shows investor Thomas English acquired 500 debentures; on a partially diluted basis, his potential ownership could rise to 27.45%, while his undiluted stake remains 13.88%. An early warning report will be filed on SEDAR+.
Trenchant Technologies Capital (OTCQB: AITTF) completed the unwinding of its acquisition of Limitless Quantum, cancelling 10,000,000 Trenchant shares and 10,000,000 Trenchant warrants with no fees or penalties and no expected material adverse impact on operations.
The company subscribed to a $1,300,000 unsecured convertible debenture of CG International Petroleum bearing 14% interest, maturing Jan 8, 2027, and received 2,309,058 warrants exercisable at $0.1126. Trenchant holds 18.84% of GNQ and an option to acquire up to 50% for $15,000,000 (expiry Nov 30, 2026); GNQ entered a business combination with IB Acquisition Corp (Nasdaq: IBAC), expected to close in Q3 2026 with a Nasdaq listing.
Trenchant Technologies Capital Corp. (CSE: AITT, OTC: AITTF) has closed its non-brokered private placement financing, generating $100,000 in gross proceeds. The company issued 400,000 units, each comprising one common share and one purchase warrant, allowing the holder to acquire an additional share at $0.50 within two years. The funds raised will be allocated to general working capital purposes. Securities from the offering are subject to a hold period of four months and one day.
GNQ Insilico has announced promising results from its AI-driven, genomics-based digital twin platform. This platform simulates human patients at a cellular level to predict drug interactions. The successful virtual trial used an existing infertility drug on digital twins, offering insights into optimizing clinical trial designs and reducing costs. GNQ's innovative technology could significantly improve drug discovery and development, reducing the typical 90% failure rate and high costs associated with bringing new drugs to market. The company's CTO emphasized the potential for this platform to refine trial design for specific patient groups before actual clinical trials.